MedTrace Logo

Effect of Reducing Phosphorus Absorption on Cardiac Biomarkers in Hemodialysis Patients

NCT01781156 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2015-03-17

No results posted yet for this study

Summary

Hyperphosphatemia and elevated cardiac biomarkers are two key characteristics of patients in end stage renal diseases(ESRD),however the majority of whom are in the absence of acute coronary syndrome(ACS). And it is still unclear why cardiac biomarkers would increase in those patients. We hypothesized that excessive phosphorus is account for that phenomenon.To confirm that hypothesis,we used one phosphorus binder to reduce phosphorus absorption in hemodialysis patients for some time and observed the change of cardiac biomarkers of those patients.

Conditions

  • End Stage Renal Failure

Sponsors & Collaborators

  • Shanghai 10th People's Hospital

    lead OTHER

Principal Investigators

  • Ai Peng, Ph.D,M.D · Shanghai 10th People's Hospital of Tongji University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2017-02-28
Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01781156 on ClinicalTrials.gov